睿知中国疾病研究地图
候选清单0

北京北京大学医学部

北京大学人民医院

Peking University People's Hospital

在本站收录的 53 种疾病中,这家医院列在其中 28 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

北京大学人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma2 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma24 篇牵头论文牵头 1 项开放试验
  3. 胃癌Stomach cancer21 篇牵头论文牵头 3 项开放试验
  4. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  5. 脊索瘤Chordoma6 篇牵头论文
  6. 骨肉瘤Osteosarcoma42 篇牵头论文牵头 2 项开放试验
  7. 胃肠道间质瘤Gastrointestinal stromal tumour8 篇牵头论文牵头 2 项开放试验
  8. 尤文肉瘤Ewing sarcoma7 篇牵头论文牵头 2 项开放试验
  9. 多发性骨髓瘤Multiple myeloma19 篇牵头论文牵头 5 项开放试验
  10. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia19 篇牵头论文牵头 4 项开放试验
  11. 再生障碍性贫血Aplastic anaemia29 篇牵头论文牵头 3 项开放试验
  12. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis7 篇牵头论文牵头 1 项开放试验
  13. 血友病 AHaemophilia A0 篇牵头论文牵头 1 项开放试验
  14. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura4 篇牵头论文牵头 2 项开放试验
  15. 范可尼贫血Fanconi anaemia2 篇牵头论文
  16. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder0 篇牵头论文牵头 1 项开放试验
  17. IgG4相关性疾病IgG4-related disease12 篇牵头论文牵头 1 项开放试验
  18. 重症肌无力Myasthenia gravis3 篇牵头论文
  19. 大动脉炎Takayasu arteritis1 篇牵头论文
  20. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  21. 白塞病Behçet disease5 篇牵头论文牵头 1 项开放试验
  22. IgA 肾病IgA nephropathy0 篇牵头论文
  23. 戈谢病Gaucher disease0 篇牵头论文
  24. 成骨不全症Osteogenesis imperfecta2 篇牵头论文
  25. 原发性胆汁性胆管炎Primary biliary cholangitis7 篇牵头论文
  26. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
  27. 先天性膈疝Congenital diaphragmatic hernia0 篇牵头论文
  28. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、神经母细胞瘤、β 地中海贫血、非典型溶血性尿毒症综合征、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、尼曼-匹克病 C 型、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.07%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

北京有 13 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题放疗手术
论文中的科室消化/肝病科
牵头的论文2
  1. Protocol to establish patient-derived xenograft and organoid for radiosensitivity of esophageal squamous cell carcinoma.2024STAR protocols免费全文
  2. The negative association between skeletal muscle and fat mass wasting caused by oesophagectomy in patients with oesophageal squamous cell carcinoma.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
中文论文(未计入)1
  1. [Feasibility of appropriately extending the surgical interval after neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
PubMed 以外找到的论文(未计入)8
  1. Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial.2025Journal of Clinical Oncology论文
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  6. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  7. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集
  8. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 24 篇,占 0.2%。

牵头论文
24
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 5520232024: 6620242025: 662025

北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    分期
    不分期
    开始
    2025-06
    登记号
    NCT07010588

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛

  2. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室普外/肝胆胰外科病理/检验科消化/肝病科影像/核医学科
牵头的论文24
  1. Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study.2025BMC medicine免费全文
  2. Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma.2025Current medicinal chemistry
  3. Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  4. Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.2025Frontiers in immunology免费全文
  5. Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients.2025The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi免费全文
  6. AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma.2025World journal of gastroenterology免费全文
  7. Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications.2024Abdominal radiology (New York)
  8. Clinical potential of serum prostaglandin A2 as a novel diagnostic biomarker for hepatocellular cancer.2024Clinica chimica acta; international journal of clinical chemistry
  9. All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines.2024International journal of molecular sciences免费全文
  10. Methodological challenges in studying immune-suppressive neutrophils in HCC models.2024Journal of hepatology
  11. For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?2024Journal of hepatology
  12. Augmentation of hepatocellular carcinoma malignancy by annexin A5 through modulation of invasion and angiogenesis.2024Scandinavian journal of gastroenterology
  13. NDRG1 facilitates self-renewal of liver cancer stem cells by preventing EpCAM ubiquitination.2023British journal of cancer免费全文
  14. A signature based on NKG2D ligands to predict the recurrence of hepatocellular carcinoma after radical resection.2023Cancer medicine免费全文
  15. The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.2023Cancer medicine免费全文
  16. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.2023Frontiers in immunology免费全文
  17. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.2023Journal for immunotherapy of cancer免费全文
  18. Outcome of near-infrared fluorescence-navigated pulmonary metastasectomy for hepatocellular carcinoma.2022European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  19. Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment.2022Frontiers in immunology免费全文
  20. The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.2022Viruses免费全文
  21. Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease.2021Biomolecules免费全文
  22. Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer.2021Frontiers in endocrinology免费全文
  23. Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  24. Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.2021The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
中文论文(未计入)2
  1. [Exploring the reasons for liver cancer occurrence still after long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Clinical application of serum Golgi protein 73 in patients with chronic liver diseases].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk即将招募NCT07010588牵头方不分期2025-06 启动
  2. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  3. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  4. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.2%。

牵头论文
21
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 4420222023: 4420232024: 3320242025: 552025

北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07857668

    年龄 20 岁 至 80 岁(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
    分期
    不分期
    开始
    2024-01
    登记号
    NCT06748690

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院北京

  3. 即将招募
    Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
    分期
    II期
    开始
    2025-10
    登记号
    NCT07018063

    年龄 16 岁 至 45 岁(登记的条件)

    牵头:北京大学人民医院北京

  4. 正在招募
    TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
    分期
    不分期
    开始
    2026-07
    登记号
    NCT07714980

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:青岛大学附属医院;另有 5 家列出的医院为研究中心Weihai、北京、潍坊、烟台、青岛

  5. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能手术早期发现与内镜
论文中的科室消化/肝病科影像/核医学科病理/检验科普外/肝胆胰外科
牵头的论文21
  1. Endoscopic semi-blunt dissection technique is safe and effective for treating gastric submucosal tumors from the muscularis propria.2025BMC gastroenterology免费全文
  2. Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy.2025Cancer treatment reviews
  3. CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.2025European radiology
  4. CXCR2P1 enhances the response of gastric cancer to PD-1 inhibitors through increasing the immune infiltration of tumors.2025Frontiers in immunology免费全文
  5. Extramural venous invasion in gastric cancer: 9.4T magnetic resonance imaging assessment and circular RNA functional analysis.2025World journal of gastroenterology免费全文
  6. Sintilimab and Cardiovascular Toxicity.2024JAMA
  7. Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration.2024Journal of translational medicine免费全文
  8. Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer.2024Journal of translational medicine免费全文
  9. Safety and efficacy of vagus nerve-preserving distal gastrectomy for early gastric cancer: A systematic review and meta-analysis.2023Asian journal of surgery
  10. Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.2023European radiologyRCT
  11. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer.2023Journal of translational medicine免费全文
  12. Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer.2023Theranostics免费全文
  13. Pathological diagnosis, differential diagnosis and origin investigation of easily misdiagnosed adult gastric duplication cysts.2022Histology and histopathology
  14. Uncut Roux-en-Y might reduce the rate of reflux gastritis after radical distal gastrectomy: An evidence mapping from a systematic review.2022International journal of surgery (London, England)
  15. Long noncoding RNA ZNFX1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPR1N1.2022World journal of gastroenterology免费全文
  16. Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.2022World journal of surgical oncology免费全文
  17. Development and evaluation of a ceMDCT-based preoperative risk stratification model to predict disease-free survival after radical surgery in patients with gastric cancer.2021Abdominal radiology (New York)
  18. A signature of 24 aging‑related gene pairs predict overall survival in gastric cancer.2021Biomedical engineering online免费全文
  19. CT-detected extramural venous invasion-related gene signature for the overall survival prediction in patients with gastric cancer.2021Cancer medicine免费全文
  20. Diagnosis of gastric lesions through a deep convolutional neural network.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  21. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
中文论文(未计入)5
  1. [Research progress on peritoneal metastasis of gastric cancer in the era of immunotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Endoscopic ultrasonographic features of submucosal lesions of upper digestive tract suspected gastrointestinal stromal tumors and their correlation with progression and pathological risk grade of the lesions].2023Zhonghua yi xue za zhi
  3. [Updates on the molecular classification of gastric cancer].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Research progress of single-incision laparoscopic radical gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)正在招募NCT07857668牵头方2026-08 启动
  2. MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT正在招募NCT06748690牵头方不分期2024-01 启动
  3. Effects of HIPEC on Postoperative Bowel Motility and Complications进行中,不再招募NCT07353177牵头方2025-04 启动
  4. Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer即将招募NCT07018063牵头方(推断)II期2025-10 启动
  5. TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)正在招募NCT07714980研究中心不分期2026-07 启动
  6. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  7. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  8. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  9. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  10. Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia已完成NCT03882281研究中心I期2019-03 启动
  11. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839研究中心III期2017-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 10 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)3
  1. [Evaluation the risk of optic nerve invasion associated with optic nerve obscuration in advanced retinoblastoma].2020[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  2. [Promoting regulated gene diagnosis for retinoblastoma in clinical work].2019[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  3. [Application of gene capture technology on mutation screening of RB1 gene in retinoblastoma patients].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 5.7%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 2220242025: 222025

北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文6
  1. CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.2025Scientific reports
  2. Multi-omics analysis unveils the role of inflammatory cancer-associated fibroblasts in chordoma progression.2025The Journal of pathology
  3. Skull base chordoma and spinal chordoma exhibit consistency in terms of endoplasmic reticulum stress aspects.2024Neuro-oncology
  4. Letter to the Editor Regarding "Hypoxia-inducible Factor-1α (HIF-1α) as a Factor to Predict Prognosis of Spinal Chordoma" by He and Liu.2024Spine
  5. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.2023Frontiers in immunology
  6. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.2023Journal for immunotherapy of cancer
中文论文(未计入)1
  1. [Analysis of influencing factors of recurrence after en bloc spondylectomy of spinal tumors].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
早期论文(2016–2020 年)6
  1. Epidemiological characteristics of 1385 primary sacral tumors in one institution in China.2020World journal of surgical oncology
  2. Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features.2019European radiology
  3. A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI.2019Journal of magnetic resonance imaging : JMRI
  4. Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging.2019The British journal of radiology
  5. miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3.2018Cell death & disease
  6. One-step reconstruction with a 3D-printed, custom-made prosthesis after total en bloc sacrectomy: a technical note.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma状态不明NCT04042597牵头方II期2019-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 42 篇,占 1.9%。

牵头论文
42
2021–2025 年
牵头试验
20
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 8820222023: 101020232024: 4420242025: 992025

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
    分期
    I/II期
    开始
    2026-03
    登记号
    NCT07479732

    年龄 12 岁 至 65 岁(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
    分期
    II期
    开始
    2024-11
    登记号
    NCT06714383

    年龄 14 岁 至 70 岁(登记的条件)

    牵头:北京大学人民医院北京

  3. 正在招募
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    分期
    II期
    开始
    2023-06
    登记号
    NCT05830123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科病理/检验科肿瘤内科
牵头的论文42
  1. Evaluating the Impact of Habitat Analysis via IVIM and DCE-MRI on Neoadjuvant Chemotherapy Outcomes in Osteosarcoma Patients: A Preliminary Study.2026Journal of imaging informatics in medicine
  2. T2-weighted magnetic resonance imaging radiogenomic features for the prediction of neoadjuvant chemotherapy response in patients with osteosarcoma.2025Acta radiologica (Stockholm, Sweden : 1987)
  3. Sonographic characteristics of local soft tissue recurrence in primary bone tumor and diagnostic efficacy versus MRI.2025BMC cancer
  4. Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.2025Cell communication and signaling : CCS
  5. Neutrophil elastase promotes low molecular weight cyclin E1 formation to accelerate osteosarcoma proliferation.2025Frontiers in immunology
  6. End-to-End Deep Learning Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Patients Using Routine MRI.2025Journal of imaging informatics in medicine
  7. Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets.2025Nano letters
  8. Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study.2025Nature communicationsRCT
  9. CD3L1 expression and its association with the tumor microenvironment in 62 cases of osteosarcoma and Chordoma.2025Scientific reports
  10. Magnetic resonance imaging assessment of epiphyseal invasion in paediatric osteosarcoma.2025Skeletal radiology
  11. Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  12. Direct contact between tumor cells and platelets initiates a FAK-dependent F3/TGF-β positive feedback loop that promotes tumor progression and EMT in osteosarcoma.2024Cancer letters
  13. Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.2024Diagnostic pathology
  14. Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma.2024Oncogene
  15. The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma.2023Autophagy
  16. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).2023BMC cancer
  17. Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.2023BMC medical imaging
  18. Clinical-radiomics models based on plain X-rays for prediction of lung metastasis in patients with osteosarcoma.2023BMC medical imaging
  19. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  20. Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.2023Clinical cancer research : an official journal of the American Association for Cancer Research
  21. Intravoxel incoherent motion and dynamic contrast-enhanced magnetic resonance imaging for neoadjuvant chemotherapy response evaluation in patients with osteosarcoma.2023European journal of radiology
  22. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.2023Orthopaedic surgery
  23. Outcomes of Semiknee Replacement in Skeletally Immature Bone Sarcoma Patients.2023The journal of knee surgery
  24. Outcomes of Fixed-Hinged Knee Prosthesis for Distal Femoral Osteosarcoma in Skeletally Immature Patients: First Results.2023The journal of knee surgery
  25. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.2022Annals of nuclear medicine
  26. Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.2022BMC cancer
  27. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.2022Cancer letters
  28. circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p.2022Cancer science
  29. Correlation of vascular endothelial growth factor with survival and pathological characteristics of patients with osteosarcoma: A systematic review and meta-analysis.2022European journal of cancer care
  30. Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.2022Frontiers in immunology
  31. How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?2022International orthopaedics
  32. Analysis of mechanical complications for patients with extremity sarcoma after biological reconstruction.2022Orthopaedics & traumatology, surgery & research : OTSR
  33. Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3.2021Aging
  34. Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment.2021Angewandte Chemie (International ed. in English)
  35. The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma.2021Annals of the New York Academy of Sciences
  36. Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China.2021BMC cancer
  37. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.2021Cancer letters
  38. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.2021Cellular oncology (Dordrecht, Netherlands)
  39. RNA-dependent protein kinase is required for interferon-γ-induced autophagy in MG63 osteosarcoma cells.2021Gene
  40. Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).2021Medicine
  41. Venous Tumor Thrombus in Primary Bone Sarcomas in the Pelvis: A Clinical and Radiographic Study of 451 Cases.2021The Journal of bone and joint surgery. American volume
  42. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.2021The oncologist
中文论文(未计入)2
  1. [Analysis of influencing factors of recurrence after en bloc spondylectomy of spinal tumors].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Pulmonary embolism secondary to osteosarcoma: a case report and literature review].2021Zhonghua xin xue guan bing za zhi
早期论文(2016–2020 年)31
  1. Multiple primary tumors: a case report and review of the literature.2020BMC musculoskeletal disorders
  2. Differentiation of Pelvic Osteosarcoma and Ewing Sarcoma Using Radiomic Analysis Based on T2-Weighted Images and Contrast-Enhanced T1-Weighted Images.2020BioMed research international
  3. Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B.2020Cancer letters
  4. Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta.2020Cancer letters
  5. Lateral malleolus en bloc resection for the distal fibula osteosarcoma based on a new classification and proposed reconstruction choice: Analysis of 6 cases prognosis and literature review.2020Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons
  6. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.2020International journal of clinical oncology
  7. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.2020Journal for immunotherapy of cancer
  8. Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.2020Journal of cellular and molecular medicine
  9. Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma.2020Journal of clinical laboratory analysis
  10. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.2020Journal of nanobiotechnology
  11. Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma.2020Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  12. Novel "double-strut" fibula ankle arthrodesis for large tumor-related bone defect of distal tibia.2019BMC musculoskeletal disorders
  13. [Rasfonin inhibits proliferation and migration of osteosarcoma 143B cells].2019Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  14. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis.2019Cancer letters
  15. Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.2019Cell death & disease
  16. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.2019The oncologist
  17. [Effectiveness of free vascularized fibular graft for bone defect after resection of lower limb malignant tumor].2019Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  18. Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?2018BMC cancer
  19. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.2018Biochemical and biophysical research communications
  20. Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono-institutional retrospective study of 115 cases.2018Cancer medicine
  21. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?2018Clinical orthopaedics and related research
  22. Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.2018International journal of oncology
  23. Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy.2018Journal of experimental & clinical cancer research : CR
  24. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.2018Journal of hematology & oncology
  25. Rectus femoris branch: An alternative blood supply for a distally based anterolateral thigh flap.2018Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  26. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma.2018Scientific reports
  27. Surgical treatment of primary malignant tumours of the distal tibia: clinical outcome and reconstructive strategies.2018The bone & joint journal
  28. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma.2017Cell death & disease
  29. Anti-angiogenesis target therapy for advanced osteosarcoma (Review).2017Oncology reports
  30. Surgical Treatment of Primary Osteosarcoma of the Sacrum: A Case Series of 26 Patients.2017Spine
  31. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.2016Journal of experimental & clinical cancer research : CR
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
  1. Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma正在招募NCT07479732牵头方I/II期2026-03 启动
  2. Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma正在招募NCT06714383牵头方II期2024-11 启动
  3. the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry进行中,不再招募NCT07593573牵头方2025-12 启动
  4. B7-H3 NIR Imaging for Osteosarcoma Surgery正在招募NCT06778603牵头方I/II期2024-01 启动
  5. Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment进行中,不再招募NCT06850506牵头方2024-09 启动
  6. Soluble B7-H3 as a Biomarker for Osteosarcoma状态不明NCT05942456牵头方2023-06 启动
  7. Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)已完成NCT05277480牵头方II期2022-03 启动
  8. Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma已暂停NCT04824352牵头方II期2021-04 启动
  9. Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma已完成NCT04690231牵头方不分期2020-12 启动
  10. Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma状态不明NCT04351308牵头方II期2020-05 启动
  11. Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study已完成NCT04546243牵头方2020-01 启动
  12. Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma已完成NCT03909776牵头方不分期2019-01 启动
  13. Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS已完成NCT03997747牵头方2019-08 启动
  14. Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab状态不明NCT03919539牵头方2019-12 启动
  15. Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma已撤回NCT04044378牵头方I/II期2019-08 启动
  16. Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma已完成NCT03359018牵头方II期2018-01 启动
  17. PD-L1 Expression in Advanced Osteosarcoma状态不明NCT03582527牵头方2018-06 启动
  18. Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum状态不明NCT03360760牵头方不分期2018-08 启动
  19. Epigenetic Biomarker for Osteosarcoma状态不明NCT03336554牵头方2017-09 启动
  20. Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy已完成NCT02711007牵头方(推断)II/III期2016-03 启动
  21. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas正在招募NCT05830123研究中心II期2023-06 启动
  22. Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure已完成NCT06935409研究中心III期2025-04 启动
  23. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma即将招募NCT05590572研究中心I/II期2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 1.5%。

牵头论文
8
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 3320232024: 0020242025: 332025

北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
    分期
    不分期
    开始
    2024-01
    登记号
    NCT06748690

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
    分期
    未注明
    开始
    2022-01
    登记号
    NCT05408897

    年龄未注明(登记的条件)

    牵头:北京大学人民医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科消化/肝病科病理/检验科
牵头的论文8
  1. Disparities in management guidelines for gastrointestinal stromal tumors: A comparison of recommendations from the Chinese Society of Clinical Oncology, National Comprehensive Cancer Network, and European Society for Medical Oncology.2025Cancer
  2. Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition).2025Cancer
  3. CT assessed morphological features can predict higher mitotic index in gastric gastrointestinal stromal tumors.2025European radiology
  4. Morphological, immunohistochemical, and genetic analyses of epithelioid gastrointestinal stromal tumors.2023Annals of diagnostic pathology
  5. Hallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis.2023European radiologyRCT
  7. Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.2021BMC gastroenterologyRCT
  8. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
中文论文(未计入)2
  1. [From following to surpassing: insight into GIST treatment development in China].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Endoscopic ultrasonographic features of submucosal lesions of upper digestive tract suspected gastrointestinal stromal tumors and their correlation with progression and pathological risk grade of the lesions].2023Zhonghua yi xue za zhi
早期论文(2016–2020 年)6
  1. Safety and efficiency of endoscopic resection versus laparoscopic resection in gastric gastrointestinal stromal tumours: A systematic review and meta-analysis.2020European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Clinical features of multiple gastrointestinal stromal tumors: A pooling analysis combined with evidence and gap map.2020World journal of gastroenterology
  3. [Evidence-based standardized diagnosis and treatment of small gastrointestinal stromal tumors].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Minimally invasive surgery for gastrointestinal stromal tumors--pursuing the trivial, or striving for perfection].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. Gastrointestinal Stromal Tumors with KIT Mutation Coexisting with Wild-type Gastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1.2018Chinese medical journal
  6. The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors.2017BMC gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT正在招募NCT06748690牵头方不分期2024-01 启动
  2. Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD正在招募NCT05408897牵头方2022-01 启动
  3. Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction邀请入组NCT07550582牵头方II期2026-04 启动
  4. A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid Biopsy已暂停NCT05867901牵头方2023-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 4.3%。

牵头论文
7
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 2220232024: 1120242025: 112025

北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07725783

    年龄 10 岁 至 60 岁(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
    分期
    I期
    开始
    2024-03
    登记号
    NCT06340204

    年龄 8 岁 至 40 岁(登记的条件)

    牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、济南

  3. 正在招募
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    分期
    I期
    开始
    2025-05
    登记号
    NCT06926283

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科
牵头的论文7
  1. Integrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.2025Cell communication and signaling : CCS
  2. Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.2024Diagnostic pathology
  3. Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma.2023BMC medical imaging
  4. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  5. Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.2022BMC cancer
  6. Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).2021Medicine
  7. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.2021The oncologist
早期论文(2016–2020 年)2
  1. Differentiation of Pelvic Osteosarcoma and Ewing Sarcoma Using Radiomic Analysis Based on T2-Weighted Images and Contrast-Enhanced T1-Weighted Images.2020BioMed research international
  2. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.2016Journal of experimental & clinical cancer research : CR
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma正在招募NCT07725783牵头方2025-09 启动
  2. Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma正在招募NCT06340204牵头方I期2024-03 启动
  3. Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma即将招募NCT07620431牵头方2026-06 启动
  4. Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment进行中,不再招募NCT06850506牵头方2024-09 启动
  5. Irinotecan and Temozolomide for Ewing Sarcoma状态不明NCT03359005牵头方II期2018-02 启动
  6. Anlotinib and Irinotecan for Ewing Sarcoma状态不明NCT03416517牵头方I/II期2018-01 启动
  7. A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors正在招募NCT06926283研究中心I期2025-05 启动
  8. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma已完成NCT05046314研究中心II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 19 篇,占 1.1%。

牵头论文
19
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 5520232024: 1120242025: 442025

北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    KPD Consolidation After ASCT in NDMM Patients
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06879379

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院;另有 1 家列出的医院为研究中心上海、北京

  2. 正在招募
    Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
    分期
    未注明
    开始
    2025-07
    登记号
    NCT07296627

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院北京

  3. 正在招募
    Risk Stratification and MRD-driven Maintenance for MM After ASCT
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06697483

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、哈尔滨

  4. 即将招募
    ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
    分期
    未注明
    开始
    2025-12
    登记号
    NCT07320326

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院北京

  5. 即将招募
    A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06369935

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院北京

  6. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  7. 正在招募
    A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
    分期
    I期
    开始
    2026-07
    登记号
    NCT07652281

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  8. 正在招募
    Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
    分期
    III期
    开始
    2025-12
    登记号
    NCT06514508

    年龄 18 岁 至 78 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  9. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛

  10. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  11. 即将招募
    A Open-Label Phase in Participants With Multiple Myeloma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07764861

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药诊断、微小残留病与危险分层双抗与抗体药物
论文中的科室肾内科影像/核医学科耳鼻喉/头颈外科病理/检验科
牵头的论文19
  1. Minimal Clonal Plasma Cell Contamination of Peripheral Stem Cell Grafts Has an Adverse Prognostic Impact in Patients with Multiple Myeloma Undergoing Autologous Transplantation.2026Acta haematologica
  2. Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment.2026Acta haematologica
  3. Safety, effectiveness and pharmacokinetics of high-dose propylene glycol-free melphalan (EVOMELA) with a prolonged infusion as myeloablative conditioning in Chinese multiple myeloma patients undergoing autologous stem cell transplantation: 2026Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  4. The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.2025Annals of hematology
  5. Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.2025BMC cancer免费全文
  6. The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050.2025Cancer letters
  7. Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China.2025Cancer medicine免费全文
  8. Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes.2024Nature communications免费全文
  9. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.2023Annals of hematologyRCT免费全文
  10. Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.2023BMC cancer免费全文
  11. Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?2023Chinese medical journal免费全文
  12. Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.2023Clinical lymphoma, myeloma & leukemiaRCT
  13. Combined crystal-storing histiocytosis, light chain proximal tubulopathy, and light chain crystalline podocytopathy in a patient with multiple myeloma: a case report and literature review.2023Renal failure免费全文
  14. Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.2022BMC cancer免费全文
  15. Radiomics Models Based on Magnetic Resonance Imaging for Prediction of the Response to Bortezomib-Based Therapy in Patients with Multiple Myeloma.2022BioMed research international免费全文
  16. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?2022Clinical lymphoma, myeloma & leukemia
  17. Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.2022International journal of biological sciences免费全文
  18. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.2021Clinical lymphoma, myeloma & leukemiaRCT
  19. Extramedullary plasmacytoma of the nasal inferior turbinate: a case report.2021The Journal of international medical research免费全文
中文论文(未计入)13
  1. [Interpretation of minimal residual disease for response evaluation in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  2. [Guidelines for the diagnosis and management of multiple myeloma: 2024 updates].2024Zhonghua nei ke za zhi
  3. [Treatment options for multiple myeloma with renal injury].2024Zhonghua nei ke za zhi
  4. [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].2024Zhonghua yi xue za zhi
  5. [Current status and challenges of immunotherapy for multiple myeloma].2024Zhonghua yi xue za zhi
  6. [A single-center retrospective analysis of 100 consecutive cases treated with lenalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma].2022Zhonghua nei ke za zhi
  7. [A message to the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)-a step further, a level higher].2022Zhonghua nei ke za zhi
  8. [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  9. [Analysis of clinical features of multiple myeloma with t(8;14)(q24;q32)].2022Zhonghua yi xue za zhi
  10. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  11. [Progress in the treatment of multiple myeloma with daratumumab].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  12. [Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  13. [Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
  1. ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab即将招募NCT07320326牵头方2025-12 启动
  2. Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients正在招募NCT07296627牵头方2025-07 启动
  3. KPD Consolidation After ASCT in NDMM Patients正在招募NCT06879379牵头方II/III期2025-03 启动
  4. Risk Stratification and MRD-driven Maintenance for MM After ASCT正在招募NCT06697483牵头方不分期2024-12 启动
  5. A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.即将招募NCT06369935牵头方2024-06 启动
  6. Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma进行中,不再招募NCT06924424牵头方不分期2025-03 启动
  7. Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement状态不明NCT05478993牵头方II期2022-10 启动
  8. Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM状态不明NCT05438394牵头方I期2022-10 启动
  9. A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma状态不明NCT01868828牵头方IV期2013-05 启动
  10. A Clinical Study of SHR-5421 in Patients With Multiple Myeloma正在招募NCT07652281研究中心I期2026-07 启动
  11. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  12. A Open-Label Phase in Participants With Multiple Myeloma即将招募NCT07764861研究中心II期2026-08 启动
  13. Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients正在招募NCT06514508研究中心III期2025-12 启动
  14. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  15. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  16. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  17. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma状态不明NCT05719701研究中心I/II期2023-03 启动
  18. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  19. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  20. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  21. Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation已完成NCT06425276研究中心IV期2020-07 启动
  22. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  23. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  24. An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants已终止NCT02761187研究中心2016-07 启动
  25. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)已终止NCT01947309研究中心2013-11 启动
  26. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma已完成NCT00689936研究中心III期2008-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 19 篇,占 8.4%。

牵头论文
19
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 5520232024: 8820242025: 222025

北京有 10 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
    分期
    III期
    开始
    2025-11
    登记号
    NCT07441291

    年龄 3 岁 至 79 岁(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
    分期
    不分期
    开始
    2024-10
    登记号
    NCT06581081

    年龄 12 岁 至 65 岁(登记的条件)

    牵头:北京大学人民医院北京

  3. 正在招募
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
    分期
    I/II期
    开始
    2024-11
    登记号
    NCT06880913

    年龄 12 岁 至 65 岁(登记的条件)

    牵头:北京大学人民医院北京

  4. 即将招募
    Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
    分期
    不分期
    开始
    2026-11
    登记号
    NCT07919470

    年龄 14 岁 至 65 岁(登记的条件)

    牵头:北京大学人民医院;另有 1 家列出的医院为研究中心北京、廊坊

  5. 正在招募
    Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
    分期
    II期
    开始
    2025-01
    登记号
    NCT07244406

    年龄 3 岁 至 25 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  6. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

  7. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    分期
    I期
    开始
    2024-09
    登记号
    NCT06927466

    年龄 3 岁 至 25 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、南昌、徐州、武汉、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童费城染色体与遗传学CAR-T 与细胞治疗
论文中的科室儿科
牵头的论文19
  1. Effective MRD clearance and long-term survival with CD19 CAR-T in pediatric B-ALL patients with MRD positivity or chemotherapy intolerance.2025Frontiers in immunology免费全文
  2. Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.2025Leukemia & lymphoma
  3. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.2024Cancer letters
  4. CD19-Specific CAR-T Cell Treatment of 115 Children and Young Adults with Acute B Lymphoblastic Leukemia: Long-term Follow-up.2024Cancer research and treatment免费全文
  5. Extracellular matrix protein 1 (ECM1) is a potential biomarker in B cell acute lymphoblastic leukemia.2024Clinical and experimental medicine免费全文
  6. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.2024Clinical lymphoma, myeloma & leukemia
  7. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.2024Hematological oncology
  8. CAR-T Therapy Followed by Hematopoietic Stem Cell Transplantation Can Improve Survival in Children Relapsed/Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia.2024Journal of pediatric hematology/oncology
  9. Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.2024Journal of translational medicine免费全文
  10. Long-Term Survival and Immune Reconstitution of Donor-Derived Chimeric Antigen Receptor T-Cell Therapy for Childhood Molecular Relapse of B-Cell Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.2024Pediatric hematology and oncology
  11. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.2023Acta haematologica
  12. CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia.2023Biomolecules & biomedicine免费全文
  13. Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor.2023Chinese medical journal免费全文
  14. Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.2023Hematological oncology
  15. The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia.2023Leukemia & lymphoma
  16. Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.2022Leukemia
  17. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.2022Pediatric hematology and oncology
  18. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.2021Clinical lymphoma, myeloma & leukemia
  19. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.2021Leukemia
中文论文(未计入)1
  1. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with TCF3/PBX1+ B-cell Acute Lymphoblastic Leukemia].2023Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT即将招募NCT07919470牵头方不分期2026-11 启动
  2. CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT正在招募NCT07441291牵头方III期2025-11 启动
  3. Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL正在招募NCT06880913牵头方I/II期2024-11 启动
  4. Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia正在招募NCT06581081牵头方不分期2024-10 启动
  5. Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL正在招募NCT07244406研究中心II期2025-01 启动
  6. A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.正在招募NCT06927466研究中心I期2024-09 启动
  7. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia正在招募NCT06450067研究中心2024-06 启动
  8. Safety and Efficacy Evaluation of IM19 CAR-T Cells状态不明NCT03142646研究中心I/II期2016-08 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 29 篇,占 7.0%。

牵头论文
29
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 101020222023: 5520232024: 3320242025: 772025

北京有 6 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07586735

    年龄 40 岁 至 60 岁(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07629947

    年龄 18 岁 至 40 岁(登记的条件)

    牵头:北京大学人民医院北京

  3. 正在招募
    A Prediction Model in Pregnant Women With Aplastic Anemia
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07101770

    年龄 20 岁 至 50 岁;仅女性(登记的条件)

    牵头:北京大学人民医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植儿童感染与支持治疗
牵头的论文29
  1. Chinese Society of Hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia.2026Chinese medical journal免费全文
  2. The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.2025Annals of hematology免费全文
  3. The haematopoietic cell transplantation comorbidity index predicts clinical outcomes for severe aplastic anaemia patients after haploidentical haematopoietic stem cell transplantation.2025Bone marrow transplantation
  4. Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: A CBMTR Registry-based propensity score matching analysis over the last decade.2025Cancer letters
  5. The Eastern Cooperative Oncology Group Score Rather Than Donor Type Impacts Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients Aged 51-60 Years: A Retrospective Study From the Chinese 2025Clinical transplantation
  6. Incidence, risk factors and clinical outcomes of primary prolonged isolated thrombocytopenia following haploidentical transplantation for severe aplastic anemia.2025Cytotherapy
  7. TGF-β inhibition restores hematopoiesis and immune balance via bone marrow EPCs in aplastic anemia.2025Experimental & molecular medicine免费全文
  8. G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Severe Aplastic Anemia Patients.2025Transplantation and cellular therapy
  9. Ovarian tissue cryopreservation after graft failure of allogeneic hematopoietic stem cell transplantation: first report and literature review.2024Frontiers in endocrinology免费全文
  10. The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese Blood and Marrow Transplant Registry group.2024Haematologica免费全文
  11. BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling.2024Signal transduction and targeted therapy免费全文
  12. Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia.2023Annals of hematology
  13. Mixed chimaerism is associated with poorer long-term failure-free survival among aplastic anaemia patients receiving HLA-matched donor transplantation.2023Bone marrow transplantation
  14. Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anem2023Bone marrow transplantation
  15. Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients.2023Frontiers in immunology免费全文
  16. Repair of dysfunctional bone marrow endothelial cells alleviates aplastic anemia.2023Science China. Life sciences
  17. Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia.2022Annals of hematology
  18. Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia.2022Bone marrow transplantation
  19. Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group.2022British journal of haematology
  20. Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation.2022British journal of haematology
  21. A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity.2022Clinical transplantation
  22. The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia.2022Frontiers in immunology免费全文
  23. Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study.2022Haematologica
  24. The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents.2022Pediatric blood & cancer
  25. Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study.2022Science bulletin
  26. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.2022The Lancet. Haematology
  27. Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges.2021Bone marrow transplantation
  28. The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia.2021Clinical transplantation
  29. Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings.2021Expert review of hematology
中文论文(未计入)5
  1. [Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [Severe cardiotoxic characteristics associated with allogeneic hematopoietic stem cell transplantation preconditioning in patients with aplastic anemia].2024Zhonghua nei ke za zhi
  3. [Causes and characteristics of pre-engraftment mortality after allogeneic hematopoietic stem cell transplantation].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  4. [Safety and survival analysis of haplo-identical hematopoietic stem cell transplantation in patients with severe aplastic anemia who had previous failure to antithymoglobulin treatment].2023Zhonghua nei ke za zhi
  5. [Erythrocytosis after hematopoietic stem cell transplantation: report of 3 cases and literature review].2023Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA正在招募NCT07586735牵头方2026-06 启动
  2. Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia正在招募NCT07629947牵头方不分期2026-06 启动
  3. A Prediction Model in Pregnant Women With Aplastic Anemia正在招募NCT07101770牵头方2025-11 启动
  4. The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA状态不明NCT06069180牵头方IV期2023-11 启动
  5. Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA状态不明NCT03821987牵头方不分期2018-12 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 7 篇,占 1.8%。

牵头论文
7
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 2220242025: 222025

北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07905066

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题EB病毒与感染诱因诊断与预后儿童
论文中的科室风湿免疫科儿科
牵头的论文7
  1. Clinical manifestations and outcomes of EBV-related secondary hemophagocytic lymphohistiocytosis.2025Annals of hematology免费全文
  2. Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.2025Lupus science & medicine免费全文
  3. Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort.2024Annals of hematology
  4. COX Regression Analysis and Mortality Risk Prediction Model of 85 Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.2024British journal of hospital medicine (London, England : 2005)
  5. A predictive model for identifying secondary underlying diseases of hemophagocytic lymphohistiocytosis.2023Frontiers in immunology免费全文
  6. Hemophagocytic Lymphohistiocytosis Secondary to Juvenile Myelomonocytic Leukemia: A Case Report and Review of the Literature.2022Journal of pediatric hematology/oncology
  7. Hemophagocytic syndrome and neurological involvement in a case of intravascular large B-cell lymphoma.2021The Journal of international medical research免费全文
中文论文(未计入)2
  1. [Ruxolitinib as an effective treatment for panniculitis associated hemophagocytic syndrome: A report of 2 cases and literature review].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
  2. [Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis].2021Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation正在招募NCT07905066牵头方2026-10 启动
  2. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])正在招募NCT07208058研究中心III期2025-11 启动
  3. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))已完成NCT07034209研究中心II期2023-04 启动
PubMed 以外找到的论文(未计入)2
  1. Analysis of Acute Leukemia-Associated Hemophagocytic Lymphohistiocytosis in Adults: A Single-Center Experience2025Immuno论文
  2. Ectopic EBV infection in T cells following allogeneic hematopoietic stem cell transplantation: Clinical outcomes and immunological characterization2025Blood会议摘要

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06727669

    年龄未注明(登记的条件)

    牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆

  2. 正在招募
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
    分期
    III期
    开始
    2026-05
    登记号
    NCT07416526

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Systemic lupus erythematosus with acquired hemophilia A: a case report].2018Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Longitudinal Cohort of Thrombosis and Hemostasis Diseases正在招募NCT06727669牵头方2024-11 启动
  2. A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A正在招募NCT07416526研究中心III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 4 篇,占 6.2%。

牵头论文
4
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06727669

    年龄未注明(登记的条件)

    牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆

  2. 正在招募
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    分期
    II期
    开始
    2024-12
    登记号
    NCT06794008

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:北京大学人民医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

北京有 3 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年没有牵头视神经脊髓炎谱系疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
    分期
    II期
    开始
    2026-08
    登记号
    NCT07809724

    年龄 18 岁 至 74 岁(登记的条件)

    牵头:北京大学人民医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder即将招募NCT07809724牵头方II期2026-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 12 篇,占 4.9%。

牵头论文
12
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 2220232024: 0020242025: 332025

北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    分期
    II期
    开始
    2024-12
    登记号
    NCT06794008

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:北京大学人民医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题头颈、眼眶与唾液腺诊断与鉴别治疗与复发
论文中的科室风湿免疫科病理/检验科
牵头的论文12
  1. Primary intraosseous Rosai-Dorfman disease: Clinicopathological features and an assessment of a possible relationship with IgG4-related disease.2025Annals of diagnostic pathology
  2. Clinical characterization of malignant lymphoma mimicking IgG4-related disease.2025Clinical rheumatology
  3. Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.2025Rheumatology (Oxford, England)
  4. Clinical profiles differ in IgG4-related disease with and without allergy: a large case-control study in China.2023Clinical and experimental rheumatology
  5. Immune phenotype changes in IgG4-related disease: CD161 + Treg and Foxp3 + Treg.2023Clinical rheumatology
  6. Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.2022Clinical and experimental rheumatology
  7. IL-7 Promotes the Expansion of Circulating CD28- Cytotoxic T Lymphocytes in Patients With IgG4-Related Disease via the JAK Signaling.2022Frontiers in immunology免费全文
  8. Characteristics of IgG4-related disease complicated with allergic rhinitis or chronic rhinosinusitis: a large cross-sectional cohort study.2022Scientific reports免费全文
  9. Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China.2021Arthritis research & therapy免费全文
  10. Needle biopsy compared with surgical biopsy: pitfalls of small biopsy in histologial diagnosis of IgG4-related disease.2021Arthritis research & therapy免费全文
  11. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study.2021Rheumatology (Oxford, England)
  12. Disparities between IgG4-related kidney disease and extrarenal IgG4-related disease in a case-control study based on 450 patients.2021Scientific reports免费全文
中文论文(未计入)1
  1. [Clinical characteristics of central nervous system involvement in IgG4 related diseases].2021Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases正在招募NCT06794008牵头方II期2024-12 启动
  2. Tofacitinib in the Treatment of IgG4 Related Diseases已完成NCT07827469牵头方不分期2023-04 启动
PubMed 以外找到的论文(未计入)5
  1. POS1249 CIRCULATING GRANZYME K+ CD8+ T CELLS UNDERLYING THE MECHANISMS OF IgG4-RELATED DISEASE2025Annals of the Rheumatic Diseases会议摘要
  2. POS0922 DIFFERENTIAL DIAGNOSIS OF FOCAL IMMUNOGLOBULIN G4-RELATED SIALADENITIS AND BENIGN SALIVARY MASSES: THE VALUE OF CONTRAST-ENHANCED ULTRASOUND2023Annals of the Rheumatic Diseases会议摘要
  3. Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity2022Rheumatology & autoimmunity论文
  4. AB0758 CLINICAL PROFILES DIFFER IN IGG4-RELATED DISEASE WITH AND WITHOUT ATOPY: A LARGE CASE-CONTROL STUDY IN CHINA2021Annals of the Rheumatic Diseases会议摘要
  5. POS1384 DIFFERENT CLINICAL CHARACTERISTICS OF IGG4-RRD PATIENTS AND NON-IGG4-RRD PATIENTS: A LARGE CHINESE COHORT STUDY2021Annals of the Rheumatic Diseases会议摘要

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题危象与重症监护生物制剂与补体抑制剂抗体与诊断
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科
牵头的论文1
  1. Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.2025Rheumatology (Oxford, England)
早期论文(2016–2020 年)1
  1. Ultrasound morphological changes in the carotid wall of Takayasu's arteritis: monitor of disease progression.2016International angiology : a journal of the International Union of Angiology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Upadacitinib for Refractory Takayasu Arteritis已完成NCT07500467牵头方(推断)2024-03 启动
  2. Baricitinib for Refractory Takayasu Arteritis已完成NCT06662721牵头方(推断)II期2023-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.0%。

牵头论文
5
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    分期
    II期
    开始
    2024-12
    登记号
    NCT06794008

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:北京大学人民医院北京

  2. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

  3. 正在招募
    AutoInflammatory Disease Alliance Registry (AIDA)
    分期
    未注明
    开始
    2020-08
    登记号
    NCT05200715

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科病理/检验科
牵头的论文5
  1. Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.2024Clinical and experimental medicine
  2. Correspondence on 'Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease'.2023Annals of the rheumatic diseases
  3. Comparison of different onset ages in patients with Behcet's disease.2023Clinical rheumatology
  4. Comment on: Efficacy and safety of tocilizumab in Behçet's syndrome with refractory arterial lesions: a single-centre observational cohort study in China: reply.2023Rheumatology (Oxford, England)
  5. Refractory Behçet's disease treated with low-dose interleukin-2: A case report.2022Medicine
中文论文(未计入)1
  1. [The distribution of biomarkers for Behcet syndrome and their clinical relevance in real-world studies].2024Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
早期论文(2016–2020 年)5
  1. [Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet's Disease.2018PloS one
  3. A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.2017Clinical and experimental rheumatology
  4. [Capsule endoscopy for Behcet's disease-treatment: five cases reports].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  5. Outcomes of surgery for patients with Behcet's disease causing aortic pseudoaneurysm: a shift from open surgery to endovascular repair.2016Clinics (Sao Paulo, Brazil)
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases正在招募NCT06794008牵头方II期2024-12 启动
  2. Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.即将招募NCT07833163牵头方II期2026-09 启动
  3. Ivarmacitinib for Refractory Behcet's Syndrome已撤回NCT07634848牵头方(推断)II期2026-06 启动
  4. Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome已完成NCT07582991牵头方(推断)II期2024-03 启动
  5. Upadacitinib for Refractory Behcet's Syndrome已完成NCT07080346牵头方(推断)II期2024-01 启动
  6. Low-dose IL-2 Treatment on Behcet's Disease已完成NCT04065672牵头方(推断)II期2021-10 启动
  7. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动
  8. AutoInflammatory Disease Alliance Registry (AIDA)正在招募NCT05200715研究中心2020-08 启动
  9. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases进行中,不再招募NCT06786338研究中心II期2025-06 启动
  2. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动
  3. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  4. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  5. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动
  6. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 5 家医院列在戈谢病下全国有 41 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)已完成NCT01074944研究中心III期2010-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

北京有 5 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 7 篇,占 2.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 4420222023: 0020232024: 1120242025: 222025

北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文7
  1. Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis.2025BMC gastroenterology
  2. Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis.2025Scientific reports
  3. The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models.2024BMC gastroenterology
  4. Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.2022Disease markers
  5. Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.2022Expert review of gastroenterology & hepatology
  6. Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.2022Medicine
  7. Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.2022Medicine
早期论文(2016–2020 年)1
  1. [Situation analysis of timing of first visit of anti-mitochondrial antibody-positive patients].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284研究中心III期2009-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis正在招募NCT07387549研究中心III期2026-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年没有牵头先天性膈疝的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 4 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. A Rare Case of Laparoscopic Repair of Simultaneously Occurring Morgagni and Paraesophageal Hernias.2016Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

北京大学人民医院

Peking University People's Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
a Peking University People's Hospital; China Peking University People's Hospital; PKUPH

提出更正下载数据